26.93
price up icon3.62%   0.94
after-market After Hours: 26.82 -0.11 -0.41%
loading
Beam Therapeutics Inc stock is traded at $26.93, with a volume of 2.05M. It is up +3.62% in the last 24 hours and down -20.07% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$25.99
Open:
$26.09
24h Volume:
2.05M
Relative Volume:
1.10
Market Cap:
$2.73B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-14.88
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
+8.90%
1M Performance:
-20.07%
6M Performance:
+59.73%
1Y Performance:
-5.74%
1-Day Range:
Value
$25.69
$27.02
1-Week Range:
Value
$25.21
$27.86
52-Week Range:
Value
$13.53
$36.44

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name
Name
Beam Therapeutics Inc
Name
Phone
857-327-8775
Name
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Employee
510
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
BEAM's Discussions on Twitter

Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BEAM
Beam Therapeutics Inc
26.93 2.64B 352.57M -143.01M -153.40M -1.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
465.02 117.03B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
783.65 82.35B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
833.54 51.64B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
308.48 42.58B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
346.42 38.87B 4.98B 69.60M 525.67M 0.5198

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-09-25 Initiated Jefferies Buy
Mar-28-25 Upgrade BofA Securities Neutral → Buy
Mar-10-25 Upgrade Scotiabank Sector Perform → Sector Outperform
Jan-29-25 Upgrade Cantor Fitzgerald Neutral → Overweight
Nov-06-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-16-24 Initiated Scotiabank Sector Outperform
Jul-23-24 Initiated H.C. Wainwright Buy
Jan-29-24 Upgrade JP Morgan Neutral → Overweight
Dec-15-23 Downgrade BofA Securities Buy → Neutral
Dec-08-23 Downgrade Jefferies Buy → Hold
Oct-20-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-20-23 Downgrade Leerink Partners Outperform → Market Perform
Mar-21-23 Initiated Bernstein Mkt Perform
Feb-01-23 Initiated Cantor Fitzgerald Overweight
Dec-20-22 Upgrade BMO Capital Markets Market Perform → Outperform
Dec-13-22 Initiated Citigroup Buy
Jun-17-22 Initiated BMO Capital Markets Market Perform
Apr-28-22 Initiated Credit Suisse Neutral
Jan-05-22 Initiated Guggenheim Buy
Oct-19-21 Initiated SVB Leerink Outperform
Sep-24-21 Resumed Stifel Buy
Sep-10-21 Initiated BofA Securities Buy
May-11-21 Initiated Redburn Buy
May-04-21 Initiated RBC Capital Mkts Sector Perform
Mar-01-21 Downgrade Barclays Overweight → Equal Weight
Feb-16-21 Initiated Wells Fargo Overweight
Jan-29-21 Downgrade JP Morgan Overweight → Neutral
Jan-06-21 Initiated Stifel Hold
Aug-05-20 Initiated William Blair Outperform
Mar-02-20 Initiated Barclays Overweight
Mar-02-20 Initiated JP Morgan Overweight
Mar-02-20 Initiated Jefferies Buy
Mar-02-20 Initiated Wedbush Outperform
View All

Beam Therapeutics Inc Stock (BEAM) Latest News

pulisher
08:30 AM

Trading Recap: Can Beam Therapeutics Inc sustain its profitabilitySell Signal & AI Enhanced Trading Alerts - baoquankhu1.vn

08:30 AM
pulisher
04:44 AM

Beam Therapeutics Secures Standby License for Key Patents - TipRanks

04:44 AM
pulisher
06:59 AM

Buyout Rumor: Will Alector Inc stock hit new highs in YEAR2025 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn

06:59 AM
pulisher
04:51 AM

Volume Summary: What is Beam Therapeutics Incs debt to equity ratioJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - baoquankhu1.vn

04:51 AM
pulisher
04:42 AM

Understanding Momentum Shifts in (BEAM) - Stock Traders Daily

04:42 AM
pulisher
03:24 AM

Aug Reactions: What is Beam Therapeutics Incs debt to equity ratioJuly 2025 Fed Impact & Verified Technical Trade Signals - baoquankhu1.vn

03:24 AM
pulisher
Feb 11, 2026

FMR LLC's Strategic Acquisition of Beam Therapeutics Inc. Shares - GuruFocus

Feb 11, 2026
pulisher
Feb 10, 2026

Beam Therapeutics Inc. (BEAM) Stock Analysis: A Biotech Innovator with 73% Potential Upside - DirectorsTalk Interviews

Feb 10, 2026
pulisher
Feb 09, 2026

Beam Therapeutics Meets 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily

Feb 09, 2026
pulisher
Feb 08, 2026

Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to Sell - MarketBeat

Feb 08, 2026
pulisher
Feb 06, 2026

Top CRISPR Companies for 2026 and How to Invest - The Motley Fool

Feb 06, 2026
pulisher
Feb 06, 2026

IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 188,243 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat

Feb 06, 2026
pulisher
Feb 05, 2026

Beam Therapeutics announces upcoming board member resignation - TipRanks

Feb 05, 2026
pulisher
Feb 03, 2026

Bear Alert: Can Beam Therapeutics Inc. sustain its profitability2025 Stock Rankings & Safe Entry Point Identification - baoquankhu1.vn

Feb 03, 2026
pulisher
Feb 03, 2026

Beam Therapeutics Inc. (BEAM) Stock Analysis: A 69% Upside Potential in the Biotech Arena - DirectorsTalk Interviews

Feb 03, 2026
pulisher
Feb 03, 2026

Beam Therapeutics: A Critical Year for Clinical Validation - AD HOC NEWS

Feb 03, 2026
pulisher
Feb 01, 2026

Y Intercept Hong Kong Ltd Takes Position in Beam Therapeutics Inc. $BEAM - MarketBeat

Feb 01, 2026
pulisher
Feb 01, 2026

Avoiding Lag: Real-Time Signals in (BEAM) Movement - Stock Traders Daily

Feb 01, 2026
pulisher
Feb 01, 2026

Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933 - Yahoo Finance

Feb 01, 2026
pulisher
Jan 31, 2026

Privium Fund Management B.V. Acquires Shares of 61,000 Beam Therapeutics Inc. $BEAM - MarketBeat

Jan 31, 2026
pulisher
Jan 31, 2026

Wall Street Zen Upgrades Beam Therapeutics (NASDAQ:BEAM) to Hold - MarketBeat

Jan 31, 2026
pulisher
Jan 29, 2026

Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) - Finviz

Jan 29, 2026
pulisher
Jan 29, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Jan 29, 2026
pulisher
Jan 28, 2026

ARK Investment Acquires 116K Shares of Beam Therapeutics (BEAM) - GuruFocus

Jan 28, 2026
pulisher
Jan 28, 2026

Beam Therapeutics Inc. (BEAM) Stock Analysis: A Look at the 46.90% Potential Upside and Cutting-Edge Genetic Medicine Advancements - DirectorsTalk Interviews

Jan 28, 2026
pulisher
Jan 26, 2026

Christine Bellon Sells 1,371 Shares of Beam Therapeutics (NASDAQ:BEAM) Stock - MarketBeat

Jan 26, 2026
pulisher
Jan 23, 2026

Beam Therapeutics (NASDAQ:BEAM) Shares Down 7.6%Here's Why - MarketBeat

Jan 23, 2026
pulisher
Jan 23, 2026

Sickle Cell Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics, Graphite Bio, Roche - Barchart.com

Jan 23, 2026
pulisher
Jan 23, 2026

JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - 富途资讯

Jan 23, 2026
pulisher
Jan 23, 2026

William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating - 富途资讯

Jan 23, 2026
pulisher
Jan 23, 2026

Cathie Wood Sells Beam Therapeutics Stock, Buys WeRide and Tempus AI - Blockonomi

Jan 23, 2026
pulisher
Jan 23, 2026

Cathie Wood Sells $5 Million Beam Therapeutics Stock, Buys WeRide and Tempus AI - CoinCentral

Jan 23, 2026
pulisher
Jan 23, 2026

Campbell & CO Investment Adviser LLC Lowers Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat

Jan 23, 2026
pulisher
Jan 23, 2026

Is Beam Therapeutics Inc forming a breakout pattern2025 Key Highlights & Free Community Consensus Stock Picks - baoquankhu1.vn

Jan 23, 2026
pulisher
Jan 23, 2026

Beam soars 22% as FDA signs off on its ambitious gene-editing plan - MSN

Jan 23, 2026
pulisher
Jan 23, 2026

Growth Report: Is Butterfly Network Inc Equity Warrant stock a buy or sellMarket Sentiment Summary & Advanced Technical Signal Analysis - baoquankhu1.vn

Jan 23, 2026
pulisher
Jan 22, 2026

cathie wood’s ARK sells beam therapeutics stock, buys weride and tempus ai By Investing.com - Investing.com India

Jan 22, 2026
pulisher
Jan 22, 2026

cathie wood’s ARK sells beam therapeutics stock, buys weride and tempus ai - Investing.com

Jan 22, 2026
pulisher
Jan 22, 2026

Beam Therapeutics (NASDAQ:BEAM) Trading 11.1% HigherWhat's Next? - MarketBeat

Jan 22, 2026
pulisher
Jan 22, 2026

Cathie Wood Dumps Beam Therapeutics, Loads Up on Netflix Stock - Blockonomi

Jan 22, 2026
pulisher
Jan 22, 2026

Cathie Wood’s ARK ETFs Buy Netflix, Sell Beam Therapeutics in Latest Moves - CoinCentral

Jan 22, 2026
pulisher
Jan 22, 2026

Beacon trial data makes Beam Therapeutics (BEAM) an attractive buy - MSN

Jan 22, 2026
pulisher
Jan 21, 2026

Analysts’ Opinions Are Mixed on These Healthcare Stocks: TransMedics Group (TMDX), Beam Therapeutics (BEAM) and Boston Scientific (BSX) - The Globe and Mail

Jan 21, 2026
pulisher
Jan 21, 2026

Insider Sell: Bethany Cavanagh Sells Shares of Beam Therapeutics Inc (BEAM) - GuruFocus

Jan 21, 2026
pulisher
Jan 21, 2026

Beam Therapeutics (BEAM) Receives Rating Update with Raised Pric - GuruFocus

Jan 21, 2026
pulisher
Jan 21, 2026

Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway By Investing.com - Investing.com India

Jan 21, 2026
pulisher
Jan 21, 2026

Bernstein raises Beam Therapeutics stock price target to $41 on FDA pathway - Investing.com Nigeria

Jan 21, 2026
pulisher
Jan 21, 2026

Discipline and Rules-Based Execution in BEAM Response - Stock Traders Daily

Jan 21, 2026
pulisher
Jan 20, 2026

Insider Selling: Beam Therapeutics (NASDAQ:BEAM) Insider Sells 18,629 Shares of Stock - MarketBeat

Jan 20, 2026
pulisher
Jan 19, 2026

SG Americas Securities LLC Purchases 36,004 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat

Jan 19, 2026
pulisher
Jan 19, 2026

JPM26: Beam, Cabaletta, More Zero In on Regulatory Alignment After Tumultuous Year - BioSpace

Jan 19, 2026

Beam Therapeutics Inc Stock (BEAM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$44.80
price up icon 1.24%
$26.75
price down icon 0.19%
$100.75
price up icon 1.93%
$105.76
price down icon 3.31%
$146.17
price down icon 1.52%
biotechnology ONC
$346.42
price down icon 1.38%
Cap:     |  Volume (24h):